These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35890180)

  • 1. Chronic Pruritus in Atopic Patients Treated with Dupilumab: Real Life Response and Related Parameters in 354 Patients.
    Mastorino L; Rosset F; Gelato F; Ortoncelli M; Cavaliere G; Quaglino P; Ribero S
    Pharmaceuticals (Basel); 2022 Jul; 15(7):. PubMed ID: 35890180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective Study of Dupilumab Treatment for Moderate to Severe Atopic Dermatitis in Korea: Efficacy and Safety of Dupilumab in Real-World Practice.
    Jang DH; Heo SJ; Jung HJ; Park MY; Seo SJ; Ahn J
    J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32599878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Response and Quality of Life in Patients with Severe Atopic Dermatitis Treated with Dupilumab: A Single-Center Real-Life Experience.
    Ferrucci S; Casazza G; Angileri L; Tavecchio S; Germiniasi F; Berti E; Marzano AV; Genovese G
    J Clin Med; 2020 Mar; 9(3):. PubMed ID: 32183179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Effectiveness of Dupilumab in Adult and Adolescent Patients with Atopic Dermatitis: 2-Year Interim Data from the PROSE Registry.
    Simpson EL; Lockshin B; Lee LW; Chen Z; Daoud M; Korotzer A
    Dermatol Ther (Heidelb); 2024 Jan; 14(1):261-270. PubMed ID: 38175364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials.
    Griffiths C; de Bruin-Weller M; Deleuran M; Fargnoli MC; Staumont-Sallé D; Hong CH; Sánchez-Carazo J; Foley P; Seo SJ; Msihid J; Chen Z; Cyr SL; Rossi AB
    Dermatol Ther (Heidelb); 2021 Aug; 11(4):1357-1372. PubMed ID: 34142350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the Relationship Between Dermatology Life Quality Index, Eczema Area and Severity Index, and Sleep Numerical Rating Scale and Pruritus Numerical Rating Scale in Patients with Atopic Dermatitis Treated with Dupilumab.
    Russo F; Cioppa V; Cartocci A; De Piano E; Taddeucci P; Lazzeri L; Santi F; Rubegni P
    Dermatitis; 2023; 34(5):440-444. PubMed ID: 36917539
    [No Abstract]   [Full Text] [Related]  

  • 7. Dupilumab treatment induced similar improvements in signs, symptoms, and quality of life in adults with moderate-to-severe atopic dermatitis with baseline Eczema Area and Severity Index Score <24 or ≥24.
    Offidani A; Stingeni L; Neri I; Cipriani F; Chen Z; Rossi AB; Lu Y; Moretti D
    Ital J Dermatol Venerol; 2022 Feb; 157(1):39-46. PubMed ID: 33878856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Dupilumab in Chinese Patients With Atopic Dermatitis: A Real-World Study.
    Zhou B; Peng C; Li L; Liu R; Zhu L; Chen X; Li J
    Front Med (Lausanne); 2022; 9():838030. PubMed ID: 35402441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploration of biomarkers to predict clinical improvement of atopic dermatitis in patients treated with dupilumab: A study protocol.
    Nakahara T; Izuhara K; Onozuka D; Nunomura S; Tamagawa-Mineoka R; Masuda K; Ichiyama S; Saeki H; Kabata Y; Abe R; Ohtsuki M; Kamiya K; Okano T; Miyagaki T; Ishiuji Y; Asahina A; Kawasaki H; Tanese K; Mitsui H; Kawamura T; Takeichi T; Akiyama M; Nishida E; Morita A; Tonomura K; Nakagawa Y; Sugawara K; Tateishi C; Kataoka Y; Fujimoto R; Kaneko S; Morita E; Tanaka A; Hide M; Aoki N; Sano S; Matsuda-Hirose H; Hatano Y; Takenaka M; Murota H; Katoh N; Furue M
    Medicine (Baltimore); 2020 Sep; 99(38):e22043. PubMed ID: 32957324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2.
    Cork MJ; Eckert L; Simpson EL; Armstrong A; Barbarot S; Puig L; Girolomoni G; de Bruin-Weller M; Wollenberg A; Kataoka Y; Remitz A; Beissert S; Mastey V; Ardeleanu M; Chen Z; Gadkari A; Chao J
    J Dermatolog Treat; 2020 Sep; 31(6):606-614. PubMed ID: 31179791
    [No Abstract]   [Full Text] [Related]  

  • 11. A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK-Irish A-STAR register.
    Alexander H; Malek R; Prieto-Merino D; Gribaleva E; Baden M; Beattie P; Brown S; Burton T; Cameron S; Coker B; Cork MJ; Hearn R; Ingram JR; Irvine AD; Johnston GA; Lambert A; Lunt M; Man I; Newell L; Ogg G; Patel P; Wan M; Warren RB; Woolf R; Yiu ZZN; Reynolds N; Ardern-Jones MR; Flohr C;
    Br J Dermatol; 2024 Jul; ():. PubMed ID: 39044673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study.
    Johansson EK; Ivert LU; Bradley B; Lundqvist M; Bradley M
    BMC Dermatol; 2020 Sep; 20(1):8. PubMed ID: 32962676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of atopic dermatitis with dupilumab: experience from a tertiary referral centre.
    Olesen CM; Holm JG; Nørreslet LB; Serup JV; Thomsen SF; Agner T
    J Eur Acad Dermatol Venereol; 2019 Aug; 33(8):1562-1568. PubMed ID: 30959559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
    Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
    Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Dupilumab on Itch-Related Events in Atopic Dermatitis: Implications for Assessing Treatment Efficacy in Clinical Practice.
    Kishi R; Toyama S; Tominaga M; Kamata Y; Komiya E; Kaneko T; Suga Y; Takamori K
    Cells; 2023 Jan; 12(2):. PubMed ID: 36672173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Dupilumab in 543 Adult Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Retrospective Study.
    Nettis E; Ferrucci SM; Ortoncelli M; Pellacani G; Foti C; Di Leo E; Patruno C; Rongioletti F; Argenziano G; Macchia L; Tavecchio S; Napolitano M; Ribero S; Bonzano L; Romita P; Di Bona D; Nisticò SP; Piras V; Calabrese G; Detoraki C; Carbonara M; Fabbrocini G
    J Investig Allergol Clin Immunol; 2022 Apr; 32(2):124-132. PubMed ID: 32856595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 52 weeks dupilumab treatment for moderate to severe atopic dermatitis in Korea: long-term efficacy and safety in real world.
    Jang DH; Heo SJ; Kook HD; Lee DH; Jung HJ; Park MY; Ahn J
    Sci Rep; 2021 Dec; 11(1):23539. PubMed ID: 34876623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of dupilumab on sleep disturbances in adult patients with severe atopic dermatitis.
    Milanesi N; Gola M; Cartocci A; Tronconi G; Bruzziches F; Flori ML; Rubegni P; Russo F
    Ital J Dermatol Venerol; 2022 Apr; 157(2):142-145. PubMed ID: 34282867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dupilumab Treatment Efficacy and Impact on Clinical Scores, Serum Biomarkers, and Itch in Adult Patients with Atopic Dermatitis: A Retrospective Analysis.
    Rossi M; Bettolini L; Artelli GL; Fraghì A; Tomasi C; Calzavara-Pinton P
    J Asthma Allergy; 2023; 16():1233-1240. PubMed ID: 37965272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-Reported Outcome Measures in Atopic Dermatitis and Chronic Hand Eczema in Adults.
    Barrett A; Hahn-Pedersen J; Kragh N; Evans E; Gnanasakthy A
    Patient; 2019 Oct; 12(5):445-459. PubMed ID: 31270775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.